Ulcerative Colitis
Coverage of Ulcerative Colitis in the Nexus archive.
- Abivax stock surges as new trial data ease cancer fears over bowel disease drug
Abivax stock surged following new Phase 3 trial data indicating malignancy rates among ulcerative colitis patients align with typical expectations, easing concerns about cancer risks linked to the bowel disease drug.
- STAT+: Abivax seeks to ease safety concerns with new data, boosting shares
Abivax released additional data on its experimental ulcerative colitis drug obefazimod to address safety concerns, leading to a 25% rise in U.S.-listed shares. The drug showed strong efficacy in a maintenance trial, but prior cancer cases among participants had raised safety risks.
- STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting
A radiopharmaceutical shows promise in the post-Pluvicto setting. Vera Therapeutics and the FDA agreed to accelerate analysis of a Phase 3 study for atacicept in treating IgA nephropathy, while Abivax reported positive data for an ulcerative colitis treatment despite cancer concerns.
- STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
Abivax's experimental drug obefazimod showed strong efficacy in a Phase 3 trial for ulcerative colitis, with over 50% of participants achieving clinical remission. However, the company's shares dropped after reporting cancer cases among treated patients, raising safety concerns.
- FDA to weigh lifting restrictions on some MAHA-favored peptides
The FDA is considering lifting restrictions on certain peptides favored by MAHA, with an advisory panel meeting in July to discuss allowing compounding pharmacies to manufacture these peptides for conditions like ulcerative colitis, wound healing, and obesity. The decision aims to address safety concerns while expanding access to treatments.